Rosen Law Firm Alerts Edwards Lifesciences Investors About Class Action Deadline

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) --

WHY: The Rosen Law Firm, a prominent global law firm focused on investor rights, has issued a reminder for those who purchased shares of Edwards Lifesciences Corporation (NYSE: EW) during the period from February 6, 2024, to July 24, 2024 (referred to as the "Class Period"). They need to be aware of the critical December 13, 2024 deadline for lead plaintiffs.

SO WHAT: Investors who acquired shares of Edwards Lifesciences within the Class Period might be entitled to financial compensation at no extra cost to them, thanks to a contingency fee system that the Rosen Law Firm offers.

WHAT TO DO NEXT: If you would like to participate in the Edwards Lifesciences class action, please visit this link or contact Phillip Kim, Esq. at 866-767-3653 or via email at [email protected] for further details. A class action lawsuit is already underway. If you want to be the lead plaintiff in this case, you must file your request with the Court by December 13, 2024. The lead plaintiff acts on behalf of other members of the class and guides the legal process.

WHY CHOOSE ROSEN LAW: It is recommended that investors opt for a law firm with proven expertise and a successful track record in leadership within securities litigation. Many firms sending out notices may lack essential experience or the necessary resources. In fact, numerous such firms do not actively litigate securities class actions; instead, they merely connect clients to other firms that handle the cases. It is wise to choose experienced counsel. The Rosen Law Firm serves investors globally, primarily focusing on securities class actions and related litigation. The firm previously secured the largest settlement in a securities class action against a Chinese company at that time and has consistently ranked highly for the number of settlements achieved. With hundreds of millions of dollars recovered for investors, their reputation is backed by significant years of success, including over $438 million returned to investors in 2019 alone. Furthermore, the firm's managing partner, Laurence Rosen, has been recognized as a leading figure in the plaintiffs' bar by Law360.

DETAILS OF THE CASE: According to court documents, during the Class Period, the company allegedly provided misleading information about their projected revenue for the fiscal year 2024, particularly regarding the growth of their key product, Transcatheter Aortic Valve Replacement (TAVR). The firm claims that the executives expressed strong confidence in the TAVR platform and emphasized the potential for growth by targeting patients who had yet to be treated. They also reportedly indicated robust demand in newly accessible markets. However, when the true information was revealed, investors faced financial losses, giving rise to this lawsuit.

To join the Edwards class action, please visit this link or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for additional details.

Please note that currently, no class has been certified. Until that happens, you are not represented by any counsel unless you formally choose one. You also have the option to remain an absent class member and take no action if you wish. Your chance of receiving any possible compensation isn't contingent upon acting as a lead plaintiff.

Stay updated with us on LinkedIn at LinkedIn, Twitter at Twitter, and Facebook at Facebook.

Attorney Advertising. Previous results do not guarantee the same outcome in the future.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Phone: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

Email: [email protected]

Website: www.rosenlegal.com

Edwards, lawsuit, investors